SGLT2 Inhibitors and the Risk for Dialysis and CVD in Patients With Stage 5 CKD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Internal Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease
Ann. Intern. Med 2024 Apr 30;[EPub Ahead of Print], FS Yen, CM Hwu, JS Liu, YL Wu, K Chong, CC HsuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.